What question did this study set out to answer?

To evaluate whether baseline plasma soluble glycoprotein VI (sGPVI) levels correlate with platelet aggregation and predict ischemic or bleeding complications in patients undergoing elective percutaneous coronary intervention (PCI).

August 17, 2023Thrombosis and Haemostasis

Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention

View Full Paper

Ask AI

Bookmark

Key result

No clinical study data was found in the provided text, which only contains journal editorial board information.

Why the study?

Soluble glycoprotein VI had not been investigated in patients with chronic coronary syndrome undergoing PCI regarding its potential value as a predictor of ischemic and bleeding risk.

Does baseline plasma soluble Glycoprotein VI (sGPVI) predict bleeding and ischemic events in patients with chronic coronary syndrome undergoing elective percutaneous coronary intervention?

Key Points

To evaluate whether baseline plasma soluble glycoprotein VI (sGPVI) levels correlate with platelet aggregation and predict ischemic or bleeding complications in patients undergoing elective percutaneous coronary intervention (PCI).
Measured baseline plasma sGPVI concentrations in 318 patients with chronic coronary syndrome undergoing elective PCI.
Assessed platelet function using adenosine diphosphate (ADP)- and collagen-induced platelet aggregation at baseline and 48 hours post-PCI following antiplatelet loading.
Evaluated co-primary endpoints: a composite ischemic outcome (death or myocardial injury) at 48 hours and BARC type 1 to 5 bleeding events at 30 days.
Baseline sGPVI levels showed no significant correlation with ADP- or collagen-induced platelet aggregation before PCI or at 48 hours post-procedure.
Composite ischemic event incidence at 48 hours did not significantly differ across sGPVI tertiles, occurring in 25.0% of the lowest, 22.9% of the middle, and 26.7% of the highest tertile (p = 0.82).
Bleeding incidence at 30 days exhibited a significant nonlinear relationship with sGPVI, occurring in 11.8% of the lowest, 12.6% of the middle, and 26.4% of the highest tertile (p = 0.006).

Structured PICO

Does baseline plasma soluble Glycoprotein VI (sGPVI) predict bleeding and ischemic events in patients with chronic coronary syndrome undergoing elective percutaneous coronary intervention?

Population

318 patients with chronic coronary syndrome (CCS) undergoing elective percutaneous coronary intervention (PCI)

Intervention

Baseline plasma soluble Glycoprotein VI (sGPVI) levels

Outcome

Co-primary endpoints of a composite of death or myocardial injury at 48 hours after PCI, and Bleeding Academic Research Consortium (BARC) type 1 to 5 bleeding at 30 dayscomposite

In patients with chronic coronary syndrome undergoing PCI, higher baseline sGPVI levels predict an increased 30-day bleeding risk but not ischemic events.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Higher sGPVI may flag post-PCI bleeding risk in CCS without ischemic excess; leaves open biomarker utility pending validation.

Cite This Study

Lahu et al. (2023) studied this question. No clinical study data was found in the provided text, which only contains journal editorial board information.

synapsesocial.com/papers/6a6de80bac440176ef274fee https://doi.org/10.1055/s-0043-1772221

Topics

Dual antiplatelet therapy Percutaneous coronary intervention

View Full Paper

Ask AI

Bookmark